Table 1 Characteristics of the ITT study population
From: Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial
Characteristics | Overall n = 400 (%) | SoC n = 200 (%) | TT n = 200 (%) |
|---|---|---|---|
Age (years) | |||
Median (range) | 61 (22–85) | 60 (34–84) | 62 (22–85) |
Gender | |||
Male | 192 (48.0) | 100 (50.0) | 92 (46.0) |
Female | 208 (52.0) | 100 (50.0) | 108 (54.0) |
Ethnicity | |||
Caucasian | 392 (98.1) | 196 (98.0) | 196 (98.0) |
Asian | 2 (0.5) | 0 (0.0) | 2 (1.0) |
Hispanic | 3 (0.8) | 2 (1.0) | 1 (0.5) |
African American | 1 (0.2) | 1 (0.5) | 0 (0.0) |
Other | 1 (0.2) | 0 (0.0) | 1 (0.5) |
NA | 1 (0.2) | 1 (0.5) | 0 (0.0) |
Primary tumor | |||
Colorectal | 65 (16.2) | 31 (15.5) | 34 (17.0) |
Breast | 40 (10.0) | 20 (10.0) | 20 (10.0) |
Gastric | 36 (9.0) | 19 (9.5) | 17 (8.5) |
Glioblastoma | 36 (9.0) | 21 (10.5) | 15 (7.5) |
Biliary tract/gallbladder | 35 (8.8) | 10 (5.0) | 25 (12.5) |
NSCLC | 35 (8.8) | 18 (9.0) | 17 (8.5) |
Ovarian | 18 (4.5) | 8 (4.0) | 10 (5.0) |
Pancreatic | 18 (4.5) | 10 (5.0) | 8 (4.0) |
Melanoma | 13 (3.2) | 8 (4.0) | 5 (2.5) |
Anus | 11 (2.8) | 5 (2.5) | 6 (3.0) |
Othersa | 93 (23.2) | 50 (25.0) | 43 (21.5) |
ECOG PS | |||
0 | 237 (59.3) | 116 (58.0) | 121 (60.5) |
1 | 162 (40.4) | 83 (41.5) | 79 (39.5) |
2 | 1 (0.3) | 1 (0.5) | 0 (0.0) |
Previous treatment lines | |||
One | 204 (51.0) | 99 (50.0) | 105 (52.0) |
Two | 196 (49.0) | 101 (50.0) | 95 (48.0) |
